Clinical Trials

535 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04080804 2026-02-09

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

80 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07392320 2026-02-06

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

142 enrolled

Nasopharangeal Cancer

NCT06468280 2026-01-21

ROSETTE

84 enrolled

Stomach Neoplasms

NCT06475300 2026-01-21

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

570 enrolled

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

40 enrolled

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT06008054 2025-09-26

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

376 enrolled

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

35 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

55 enrolled

Rectal Neoplasms

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

120 enrolled

CNS

Neuroblastoma

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT06437509 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

66 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06437522 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06471205 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

52 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT06758037 2025-03-18

HiR+X

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

46 enrolled

Locally Advanced Rectal Cancer

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT05555888 2025-01-15

TORCH-E

34 enrolled

Early Low Rectal Cancer

NCT05972655 2025-01-09

mRCAT

32 enrolled

Low Rectal Cancer

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT06455124 2024-06-13

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

60 enrolled

Rectal Neoplasms

NCT06396637 2024-05-02

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

20 enrolled

Pancreatic Adenocarcinoma Metastatic

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

39 enrolled

Nasopharyngeal Carcinoma

NCT06170710 2023-12-14

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

173 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06121700 2023-11-08

Miracle-G

55 enrolled

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT06122493 2023-11-08

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

112 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05961761 2023-07-27

PROPANE

80 enrolled

Sarcoma

Hemangiosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT05213884 2023-05-06

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

30 enrolled